Omvoh, Crohn's disease

FDA Approves Omvoh for Moderately to Severely Active Crohn Disease
The U.S. Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to sever
Omvoh Approved for Crohn's; Fitbit Predicts IBD Flares; H. Pylori and Gastric Cancer
The FDA expanded the approval of mirikizumab (Omvoh) to include treatment of adults with moderately to severely active Crohn's disease, drugmaker Eli Lilly announced; the first-in-class interleukin-23 antagonist was previously approved for ulcerative colitis.
Lilly’s Omvoh approved by FDA for Crohn’s
The clearance broadens use of Omvoh, which is part of a slate of new medicines Lilly is counting on to build on its success in diabetes and obesity.
Eli Lilly’s Omvoh granted FDA approval to treat Crohn’s disease in adults
The drug is already approved in the US to treat ulcerative colitis, another form of inflammatory bowel disease
FDA Okays LLY's Omvoh for Second Inflammatory Bowel Disease Condition
Eli Lilly and Company LLY announced that the FDA has granted approval to its drug, Omvoh (mirikizumab), for its second inflammatory bowel disease (IBD) condition, Crohn's disease (“CD”), in the United States.
FDA Approves Lilly’s Omvoh for Crohn's Disease, Second Indication
More than half (53%) of patients reached remission after one year of Omvoh treatment and 46% experienced healing of the intestinal tract, when compared to placebo.
Lilly nets a second FDA okay for Omvoh, in Crohn's disease
Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.
FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease
Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease in adults.
IBD drug market rattles as Lilly’s Omvoh nabs FDA approval for second IL-23p19 in Crohn’s
The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second interleukin-23p19 specific inhibitor approved for both major types of inflammatory bowel disease,
Omvoh Approved for Moderately to Severely Active Crohn Disease
Mirikizumab is a humanized immunoglobulin G4 monoclonal antibody that selectively binds to the p19 subunit of human interleukin (IL)-23.
FDA Approves Eli Lilly’s Omvoh for Crohn Disease
Approval was based on results of the VIVID-1 study, which found that Omvoh demonstrated significant clinical remission and endoscopic response rates in patients with Crohn disease.
BioSpace10h
Lilly’s I&I Push Gains Momentum With Omvoh Expansion
Omvoh’s label expansion is important progress for Eli Lilly as it works to diversify its portfolio beyond obesity, according ...
Business Insider2d
Eli Lilly sees growth in 2025 from new medicines
Lilly anticipates revenue growth contributions in 2025 from new Lilly medicines such as Jaypirca, Ebglyss, Omvoh and Kisunla; approvals of new indications for existing Lilly medicines; launches of ...